TY - JOUR
T1 - Molecular epidemiology of MRSA in 13 ICUs from eight European countries
AU - behalf of the MOSAR WP3 Study Group
AU - Hetem, D. J.
AU - Derde, L. P.G.
AU - Empel, J.
AU - Mroczkowska, A.
AU - Orczykowska-Kotyna, M.
AU - Kozińska, A.
AU - Hryniewicz, W.
AU - Goossens, H.
AU - Bonten, M. J.M.
AU - Cooper, B.
AU - Malhotra-Kumar, S.
AU - Willems, R.
AU - Gniadkowski, M.
AU - Dautzenberg, M.
AU - Annane, D.
AU - Aragão, I.
AU - Chalfine, A.
AU - Esteves, F.
AU - Giamarellou, H.
AU - Muzlovic, I.
AU - Nardi, G.
AU - Petrikkos, G.
AU - Tomic, V.
AU - Torres Martí, A.
AU - Stammet, P.
AU - Brun-Buisson, C.
AU - Aires, E.
AU - Antoniadou, A.
AU - Armaganidis, A.
AU - Blairon, F.
AU - Carneiro, J.
AU - Chaskou, D.
AU - Coppadoro, P.
AU - Dias, A. P.
AU - Drinovec, I.
AU - Elia, M.
AU - Exarchou, V.
AU - Flet, A.
AU - Fournier, J.
AU - Gillet, N.
AU - Jaklič, A.
AU - Jereb, M.
AU - Kane, A.
AU - Karkali, E.
AU - Kieffer, J.
AU - Kirpach, P.
AU - Landelle, C.
AU - Landercy, F.
A2 - Dumpis, U.
A2 - Melbarde-Kelmere, A.
N1 - Publisher Copyright:
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Objectives: The European epidemiology of MRSA is changing with the emergence of community-associated MRSA (CA-MRSA) and livestock-associated MRSA (LA-MRSA). In this study,we investigated the molecular epidemiology of MRSA during 2 years in 13 ICUs in France, Greece, Italy, Latvia, Luxemburg, Portugal, Slovenia and Spain. Methods: Surveillance cultures for MRSA from nose and wounds were obtained on admission and twice weekly from all patients admitted to an ICU for ≥3 days. The first MRSA isolate per patient was genotyped in a central laboratory by MLST, spa typing, agr typing and SCCmec (sub)typing. Risk factors for patients with an unknown history of MRSA colonization were identified. Results: Overall, 14390 ICU patients were screened, of whom 8519 stayed in an ICU for ≥3 days. Overall MRSA admission prevalence was 3.9% and ranged from 1.0% to 7.0% for individual ICUs. Overall MRSA acquisition rate was 2.5/1000 patient days at risk and ranged from 0.2 to 8/1000 patient days at risk per ICU. In total, 557 putative MRSA isolates were submitted to the central laboratory for typing, of which 511 (92%) were confirmed as MRSA. Each country had a distinct epidemiology, with ST8-IVc (UK-EMRSA-2/-6, USA500) being most prevalent, especially in France and Spain, and detected in ICUs in five of eight countries. Seventeen (3%) and three (<1%) isolateswere categorized as CA-MRSA and LA-MRSA, respectively. Risk factors for MRSA carriage on ICU admission were age >70 years and hospitalization within 1 year prior to ICU admission. Conclusions: The molecular epidemiology of MRSA in 13 European ICUs in eight countries was homogeneous within, but heterogeneous between, countries. CA-MRSA and LA-MRSA genotypes and Panton-Valentine leucocidin-producing isolates were detected sporadically.
AB - Objectives: The European epidemiology of MRSA is changing with the emergence of community-associated MRSA (CA-MRSA) and livestock-associated MRSA (LA-MRSA). In this study,we investigated the molecular epidemiology of MRSA during 2 years in 13 ICUs in France, Greece, Italy, Latvia, Luxemburg, Portugal, Slovenia and Spain. Methods: Surveillance cultures for MRSA from nose and wounds were obtained on admission and twice weekly from all patients admitted to an ICU for ≥3 days. The first MRSA isolate per patient was genotyped in a central laboratory by MLST, spa typing, agr typing and SCCmec (sub)typing. Risk factors for patients with an unknown history of MRSA colonization were identified. Results: Overall, 14390 ICU patients were screened, of whom 8519 stayed in an ICU for ≥3 days. Overall MRSA admission prevalence was 3.9% and ranged from 1.0% to 7.0% for individual ICUs. Overall MRSA acquisition rate was 2.5/1000 patient days at risk and ranged from 0.2 to 8/1000 patient days at risk per ICU. In total, 557 putative MRSA isolates were submitted to the central laboratory for typing, of which 511 (92%) were confirmed as MRSA. Each country had a distinct epidemiology, with ST8-IVc (UK-EMRSA-2/-6, USA500) being most prevalent, especially in France and Spain, and detected in ICUs in five of eight countries. Seventeen (3%) and three (<1%) isolateswere categorized as CA-MRSA and LA-MRSA, respectively. Risk factors for MRSA carriage on ICU admission were age >70 years and hospitalization within 1 year prior to ICU admission. Conclusions: The molecular epidemiology of MRSA in 13 European ICUs in eight countries was homogeneous within, but heterogeneous between, countries. CA-MRSA and LA-MRSA genotypes and Panton-Valentine leucocidin-producing isolates were detected sporadically.
UR - http://www.scopus.com/inward/record.url?scp=84960145838&partnerID=8YFLogxK
U2 - 10.1093/jac/dkv298
DO - 10.1093/jac/dkv298
M3 - Article
C2 - 26424737
AN - SCOPUS:84960145838
SN - 0305-7453
VL - 71
SP - 45
EP - 52
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
IS - 1
ER -